| HOME >> BIOLOGY >> TECHNOLOGY |
Toronto Stock Exchange Symbol: MS
EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX:
MS), a leading developer in the treatment of multiple sclerosis (MS), today
announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs,
will present at the Sachs Associates 8th Annual Biotech in Europe Investor
Forum in Zurich, Switzerland.
WHEN: Tuesday September 23rd at 11:25am (Local Time)
WHERE: Zurich, Switzerland
About Sachs Associates Biotech in Europe Investor Forum
-------------------------------------------------------
The forum is recognized as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and listed companies with leading investors, analysts, money managers and pharmas.
About BioMS Medical Corp.
-------------------------
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking statements, which
reflect
'/>"/>
| SOURCE BioMS Medical Corp. Copyright©2008 PR Newswire. All rights reserved |